# ICMJE DISCLOSURE FORM

Date	e: 22. februar 2024		
You	r name: Michella Dinithi	Peiris	
Mar	nuscript title: Kardiel	involvering ved EGPA; en s	jælden tilstand
Mar	nuscript number (if known)	): 1	
are re third comr list a The f	elated to the content of yo parties whose interests ma nitment to transparency ar relationship/activity/intere	ur manuscript. "Related" ay be affected by the cont nd does not necessarily in est, it is preferable that yo	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so.  ps/activities/interests as they relate to the current
perta antih In ite	ins to the epidemiology of ypertensive medication, ev	hypertension, you should yen if that medication is n port for the work reported	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript.  d in this manuscript without time limit. For all months.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial plan		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	None     Non	
	No time limit for this item.		
			Click TAD in last rought and outre rough
T'	- f		Click TAB in last row to add extra rows
Time	e frame: past 36 months		
2 Grants or contracts from		None     Non	
	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	⊠ None	
J	Noyalties of ficerises	None     Non	

4	Consulting fees	⊠ None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	⊠ None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None
11	Stock or stock options	None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None
13	Other financial or non- financial interests	None

Please place an "X" next to the following statement to indicate your agreement:

 $\boxtimes$  I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

## ICMJE DISCLOSURE FORM

Dat			
You	r name: Keld-Erik Byg		
Ma	nuscript title: Kardiel	l involvering ved EGPA; en sj	ælden tilstand
Mai	nuscript number (if known	): 1	
are re third comr list a The f	elated to the content of yo parties whose interests ma mitment to transparency a relationship/activity/intere	ur manuscript. "Related" ay be affected by the cont nd does not necessarily in est, it is preferable that yo	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit ent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so.  ps/activities/interests as they relate to the current
perta antih In ite	nins to the epidemiology of hypertensive medication, ev	hypertension, you should ven if that medication is n port for the work reported	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript.  d in this manuscript without time limit. For all months.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	e frame: Since the initial plar	whom you have this relationship or indicate none (add rows as needed) nning of the work	(e.g., if payments were made to you or to your
Tim.	e frame: Since the initial plan  All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this	whom you have this relationship or indicate none (add rows as needed) nning of the work	(e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	whom you have this relationship or indicate none (add rows as needed) nning of the work	(e.g., if payments were made to you or to your
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this	whom you have this relationship or indicate none (add rows as needed) nning of the work	(e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	whom you have this relationship or indicate none (add rows as needed) nning of the work	(e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated	whom you have this relationship or indicate none (add rows as needed) nning of the work  None	(e.g., if payments were made to you or to your institution)

4	Consulting fees	⊠ None
		<u> </u>
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None     Non
6	Payment for expert testimony	⊠ None
		<u> </u>
7	Support for attending meetings and/or travel	⊠ None
	meetings and/or traver	
8	Patents planned, issued or pending	None     Non
	perialing	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None
10	Landaudite on Caladan	
10	Leadership or fiduciary role in other board,	⊠ None
	society, committee or advocacy group, paid or	
	unpaid	
11	Stock or stock options	None     Non
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None
10	Other financial	NA Nava
13	Other financial or non- financial interests	⊠ None

Please place an "X" next to the following statement to indicate your agreement:

🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

### IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

## ICMJE DISCLOSURE FORM

Det			
Dat			
	r name: Lotte Saaby		
Mai	nuscript title: Kardiel	involvering ved EGPA; en sj	jælden tilstand
Mai	nuscript number (if known	): 1	
are re third comr list a The f	elated to the content of yo parties whose interests ma mitment to transparency a relationship/activity/intere	ur manuscript. "Related" ay be affected by the cont nd does not necessarily in est, it is preferable that yo	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so.  Os/activities/interests as they relate to the current
perta	ains to the epidemiology of	hypertension, you should	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript.
	r items, the time frame for	•	d in this manuscript without time limit. For all months.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Tim	e frame: Since the initial plar		
1	All support for the present	None     Non	
	manuscript (e.g., funding,		
	nrovision of study		
	provision of study materials, medical writing,		
	materials, medical writing, article processing charges,		
	materials, medical writing,		
	materials, medical writing, article processing charges,		
	materials, medical writing, article processing charges, etc.)		
	materials, medical writing, article processing charges, etc.)  No time limit for this		Click TAB in last row to add extra rows
Time	materials, medical writing, article processing charges, etc.)  No time limit for this		Click TAB in last row to add extra rows
	materials, medical writing, article processing charges, etc.)  No time limit for this item.		Click TAB in last row to add extra rows
Time 2	materials, medical writing, article processing charges, etc.)  No time limit for this item.  e frame: past 36 months  Grants or contracts from	None	Click TAB in last row to add extra rows
	materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	Click TAB in last row to add extra rows
2	materials, medical writing, article processing charges, etc.)  No time limit for this item.  e frame: past 36 months  Grants or contracts from any entity (if not indicated in item #1 above).		Click TAB in last row to add extra rows
	materials, medical writing, article processing charges, etc.)  No time limit for this item.  e frame: past 36 months  Grants or contracts from any entity (if not indicated	None None	Click TAB in last row to add extra rows

4	Consulting fees	None     Non
	Payment or honoraria for lectures, presentations,	None     Non
	speakers bureaus, manuscript writing or educational events	
	educational events	
6	Payment for expert testimony	⊠ None
7	Support for attending	⊠ None
	meetings and/or travel	
8	Patents planned, issued or	None     Non
	pending	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None
10	Leadership or fiduciary	⊠ None
10	role in other board,	None
	society, committee or advocacy group, paid or unpaid	
	dilpara	
11	Stock or stock options	⊠ None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None
13	Other financial or non- financial interests	None

Please place an "X" next to the following statement to indicate your agreement:

🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

### IMPORTANT for Ugeskrift for Læger & Danish Medical Journal